Results 71 to 80 of about 355,053 (311)

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real‐World Early Experience Program

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials. Objective To report findings from PrevU, an early experience, real‐world observational
Laxman Bahroo, Aaron Ellenbogen, Robert A. Hauser, Han S. Lee, Peter McAllister, Atul T. Patel, Rashid Kazerooni, Todd M. Gross, Julia Sparrow, Conor J. Gallagher, David A. Hollander   +10 more
wiley   +1 more source

Botulinum neurotoxin formulations: overcoming the confusion

Clinical, Cosmetic and Investigational Dermatology, 2018
Souphiyeh Samizadeh,1 Koenraad De Boulle2 1Great British Academy of Aesthetic Medicine, London, UK; 2Aalst Dermatology Clinic, Aalst, Belgium Abstract: Botulinum toxin A is produced by anaerobic spore-forming bacteria and is used for various therapeutic ...
Samizadeh S, De Boulle K
doaj  

An integrated, cost-effective efficient chain to deliver botulinum toxin in optimal conditions.

International Journal of Integrated Care, 2019
Introduction: Botulinum toxin is increasingly used in clinical care for a variety of conditions that include facial spasms, bleharospasms, and other abnormal movement disorders.
Marian Gomez Beldarrain, Amaia Santos Ibañez, Maria Carmen Maldonado Fernandez, Maria Jose Martinez Bengoechea, Juan Carlos Garcia-Monco   +4 more
doaj   +1 more source

Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

Acta Médica Portuguesa, 2020
Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin ...
Alexandre Camões- Barbosa, Inês Mendes Ribeiro, Luisa Medeiros   +2 more
doaj   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Long-term efficacy of spasticity-corrective surgery and botulinum toxin injections for upper limb spasticity treatment

Journal of Rehabilitation Medicine - Clinical Communications
Objective: To evaluate the long-term efficacy of spasticity-corrective surgery and botulinum toxin treatment in patients with upper limb spasticity. Design: Pretest-posttest quasi-experimental study.
Therese Ramström, Johanna Wangdell, Carina Reinholdt, Trandur Ulfarsson, Lina Bunketorp Käll   +4 more
doaj   +1 more source

Psychiatric Comorbidity, Tic Severity and Quality of Life in Adults with Tourette's Syndrome

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Psychiatric comorbidities are common in adults with Tourette's Syndrome (TS), and appear to influence both tic severity and quality of life (QOL). Objective To assess the association between psychiatric comorbidities, tic severity and QOL in TS.
Andreas Hartmann, Christelle Nilles, Yulia Worbe, Davide Martino, Naoual Serari, Catherine Deans, Isabella Davenport, Julian Fletcher, Emmanuel Roze, Tamara Pringsheim   +9 more
wiley   +1 more source

Double Sandwich ELISA Modified Method for the Detection of Clostridium Botulinum Type E [PDF]

Journal of Fasa University of Medical Sciences, 2013
Background & Objective: A very small amount of botulinum toxin can cause death and on the other hand, there is no cure for its poison other than antitoxin.
Mohammad Ebrahim minaei, Mojtaba Saadati
doaj   +1 more source

History of Botulinum Toxin Treatment in Movement Disorders

Tremor and Other Hyperkinetic Movements, 2016
Background The frontiers of clinical medicine constantly expand as a result of the innovative efforts of visionary researchers and keen observations of seasoned clinicians.
B. Jabbari
semanticscholar   +1 more source

Precisely specifying which botulinum toxin products are used for aesthetic treatments is essential

Journal of Oral Biology and Craniofacial Research, 2022
Andy Pickett
doaj   +1 more source